1. Home
  2. BRW vs CCCC Comparison

BRW vs CCCC Comparison

Compare BRW & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BRW
  • CCCC
  • Stock Information
  • Founded
  • BRW 1987
  • CCCC 2015
  • Country
  • BRW United States
  • CCCC United States
  • Employees
  • BRW N/A
  • CCCC N/A
  • Industry
  • BRW Trusts Except Educational Religious and Charitable
  • CCCC Biotechnology: Pharmaceutical Preparations
  • Sector
  • BRW Finance
  • CCCC Health Care
  • Exchange
  • BRW Nasdaq
  • CCCC Nasdaq
  • Market Cap
  • BRW 333.0M
  • CCCC 104.4M
  • IPO Year
  • BRW N/A
  • CCCC 2020
  • Fundamental
  • Price
  • BRW $8.12
  • CCCC $1.48
  • Analyst Decision
  • BRW
  • CCCC Buy
  • Analyst Count
  • BRW 0
  • CCCC 3
  • Target Price
  • BRW N/A
  • CCCC $12.00
  • AVG Volume (30 Days)
  • BRW 222.1K
  • CCCC 1.4M
  • Earning Date
  • BRW 01-01-0001
  • CCCC 07-31-2025
  • Dividend Yield
  • BRW 15.59%
  • CCCC N/A
  • EPS Growth
  • BRW N/A
  • CCCC N/A
  • EPS
  • BRW N/A
  • CCCC N/A
  • Revenue
  • BRW N/A
  • CCCC $39,783,000.00
  • Revenue This Year
  • BRW N/A
  • CCCC N/A
  • Revenue Next Year
  • BRW N/A
  • CCCC N/A
  • P/E Ratio
  • BRW N/A
  • CCCC N/A
  • Revenue Growth
  • BRW N/A
  • CCCC 98.56
  • 52 Week Low
  • BRW $7.15
  • CCCC $1.09
  • 52 Week High
  • BRW $8.30
  • CCCC $7.66
  • Technical
  • Relative Strength Index (RSI)
  • BRW 71.83
  • CCCC 48.83
  • Support Level
  • BRW $7.85
  • CCCC $1.36
  • Resistance Level
  • BRW $8.18
  • CCCC $1.60
  • Average True Range (ATR)
  • BRW 0.09
  • CCCC 0.12
  • MACD
  • BRW 0.02
  • CCCC -0.00
  • Stochastic Oscillator
  • BRW 87.18
  • CCCC 31.58

About BRW Saba Capital Income & Opportunities Fund SBI

Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: